Indications
Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy.
Composition
- Active substance
- lutetium (177Lu) vipivotide tetraxetan
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Pluvicto
- Active substance
- lutetium (177Lu) vipivotide tetraxetan
- ATC code
- V10XX
- Group
- Various
- Therapeutic area
- Prostatic Neoplasms, Castration-Resistant